DERMATOLOGY: 1 phase IV study in antibiotherapy of the erysipelas

Monitoring of 4 international studies (immunotherapy/oncology/infectious disease) : 1 phase I/II in melanoma, 1 phase I and 1 phase III in lung cancer and 1 phase II in HIV

* OUTSOURCING IN SANOFY-SYNTHELABO : 1 international phase IIIb trial in rheumatology * INSOURCING: * 2 phase I trials: allergology (antihistaminic) and medical device (new intradermic syringe) * 2 phase II international trials: oncology (breast cancer) and cardiology (anticoagulant in instable angina) * 1 phase III international trial: allergology (treatment of the seasonal allergic rhinitis) * 2 phase IV trials: rheumatology (knee osteoarthritis), neurology & pulmonology (sleep apnea) * 4 national Observational studies : cardiology, gastroenterology, pulmonology and urology * Monitoring of centres in hospital and private practice(general practitioner and physicians)

Covance, the drug development business of Laboratory Corporation of America Holdings (LabCorp), is the world's most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real by providing high-quality nonclinical, clinical and commercialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Because of our broad experience and specialized expertise, we're in a unique position to supply insights that go above and beyond testing -- We have helped pharmaceutical and biotech companies develop each of the top 50 prescription drugs in the marketplace today.We also offer laboratory testing services to the chemical, agrochemical and food industries and are a market leader in toxicology services, central laboratory services, discovery services, and a top global provider of Phase III clinical trial management services.Together with our clients, we create solutions that transform potential into reality.

New challenge in the diagnostic

* Outsourcing activities : 2 missions at the same time => at TEVA for 1 phase II international trial in neurology (amyotrophic lateral sclerosis (ALS)) and at WYETH : 1 phase III international trial in the treatment of in patients in palliative cares * Insourcing activities : Review of Clinical Monitoring Umanis's SOP and Pass Throuhg costs evaluation for proposals